Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02290691 · ClinicalTrials.gov registry record · Phase 4
Inactivated Influenza Via Jet Injection
A Phase 4 study, sponsored by PharmaJet.
- Completed
- Registry status
- Phase 4
- Development phase
- 985
- Enrollment target
NCT02290691 is a Phase 4 study that has completed, run by PharmaJet. The registered enrollment target is 985 participants.
The verdict
NCT02290691, a Phase 4 study, has completed, sponsored by PharmaJet.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 985 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the administration of flu vaccine using Needle-Free is equivalent to Needle and Syringe administration as measured by laboratory tests of immune response.
Interventions
- BIOLOGICAL Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 985 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02290691
The ClinicalTrials.gov registry entry for NCT02290691 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 985 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaJet, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza Vaccine is the first listed.
NCT02290691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02290691 about?
NCT02290691 is a clinical study titled "Inactivated Influenza Via Jet Injection". The purpose of this study is to determine if the administration of flu vaccine using Needle-Free is equivalent to Needle and Syringe administration as measured by laboratory tests of immune response.
What is the current status of trial NCT02290691?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 985 participants. The study started on 2014-11. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02290691?
The interventions under investigation include: Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02290691?
This trial is sponsored by PharmaJet, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.